StockNews.AI
AXGN
StockNews.AI
6 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

1. Pomerantz LLP is investigating Axogen for securities fraud claims. 2. The FDA extended the PDUFA date for Axogen's Avance® Nerve Graft. 3. Axogen's stock dropped 9.04% following the FDA announcement.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The ongoing investigation for securities fraud combined with regulatory delays typically negatively impacts investor confidence and stock prices. Historical instances show stock prices of companies facing similar allegations often decline significantly.

How important is it?

Given the potential for significant legal repercussions and the immediate impact on Axogen’s stock price from the FDA news, this situation is deemed high importance.

Why Short Term?

The immediate effects of regulatory and legal investigations can quickly sway market perceptions, as seen in previous cases where similar investigations led to immediate stock sell-offs.

Related Companies

AXGN
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 25, 2025, Axogen issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025.” On this news, Axogen’s stock price fell $1.47 per share, or 9.04%, to close at $14.79 per share on August 25, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News